Pfizer appoints Cecile Guegan as Chief Financial Officer

Cecile has served as interim Chief Financial Officer since August 16, 2026

by e4m Staff
Published: Nov 14, 2026 9:04 AM | 2 min read

Pfizer appoints Cecile Guegan as Chief Financial Officer

Pfizer has appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, following her role as interim CFO since August 16, 2026.
Albert Bourla, Pfizer's Chairman and CEO, praised Guegan's extensive experience and strategic vision, emphasizing her ability to optimize financial performance and drive growth.
Guegan will oversee all corporate finance functions, including audit, treasury, investor relations, and business finance, and aims to focus on disciplined capital allocation and long-term growth.
She has over 25 years of experience in finance, previously managing financial operations for Pfizer’s biopharmaceutical business and leading significant enterprise acquisitions and strategic initiatives.

Pfizer has announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026.

“Cecile is an exceptional finance leader who knows our company and industry deeply, and she has a proven track record of optimizing financial performance while fueling growth,” said Albert Bourla, Chairman and Chief Executive Officer. “Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands as we aim for meaningful growth. I’m confident she will help us execute with discipline and ambition as we work to deliver for our patients and shareholders.”

“I am honored to step into this role to continue positioning Pfizer for durable long-term growth and shareholder value creation,” said Cecile Guegan, Chief Financial Officer and Executive Vice President, Pfizer. “My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond.”

Cecile will oversee every aspect of the Company’s financial management. She will be responsible for all corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.

Prior to stepping into the interim finance leadership role, Cecile was directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. In previous positions, Cecile served as a strategic partner to group presidents and chief commercial officers, led long-term forecasting for key product portfolios, led major enterprise acquisitions and integrations and co-led a strategic initiative to identify new sources of growth.

She holds a master’s degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor’s degree in Accounting (French DECF).